Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan double upgrades Antofagasta to 'overweight'

(Sharecast News) - JPMorgan Cazenove double upgraded Antofagasta on Wednesday to 'overweight' from 'underweight' and hiked the price target to 2,400p from 1,600p citing a positive long-term copper outlook and leading medium-term copper growth. The bank said its sector view since December 2024 has been that a return to US-China trade tensions could weigh on copper prices & EMEA miners before China stimulus later in the first quarter of 2024 could drive a V-shaped recovery.

JPM said its China economists expect the upcoming 5-8 March National People's Congress meeting could deliver fiscal stimulus, including consumer support, which it believes will be supportive for copper demand and mining equities.

JPM Commodities still forecast the copper market shifting to deficit in 2025, widening to a more than 3Mt deficit by 2030.

The bank said that within EMEA mining, Antofagasta offers +15%/+30% copper growth to 2027/28E versus 2024, which is higher than peers.

"Also, we have revisited our model to incorporate the Los Pelambres & Zaldivar life extension projects to 2050, as well as the latest reserves, which together drive a circa 50% increase to our NPV," it said.

JPM also said that following FY24 results, it has revised its 2025/26 group EBITDA forecasts by +2%/+2% and lifted its price target.

"ANTO trades on spot 9.8x/9.0x 2025/26E EV/EBITDA higher versus its EMEA base metal peers, but more in-line with its larger-scale global copper peers on circa 10x," JPM said. "Thus we double upgrade to OW."

At 1000 GMT, the shares were up 1.6% at 1,865.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.